Literature DB >> 7983744

Evaluation of colocalization interactions between the IE110, IE175, and IE63 transactivator proteins of herpes simplex virus within subcellular punctate structures.

M A Mullen1, S Gerstberger, D M Ciufo, J D Mosca, G S Hayward.   

Abstract

A number of previous studies have implied that three herpes simplex virus-encoded nuclear transactivator proteins, IE175 (ICP4), IE110 (ICP0), and IE63 (ICP27), may cooperate in transcriptional and posttranscriptional stimulation of viral gene expression. Using double-label immunofluorescence assays (IFA) in transient expression assays, we have examined the intracellular localization of these three proteins in DNA-transfected cells. The IE110 protein on its own forms spherical punctate domains within the nucleus, whereas the IE175 and IE63 proteins alone give uniform and speckled diffuse patterns, respectively. In infected cells, the IE110 punctate granules have been shown to correspond to novel preexisting subnuclear structures referred to as ND10 domains or PODs that contain a variety of cellular proteins, including SP100 and the PML proto-oncogene product. Cotransfection experiments with wild-type nuclear forms of both IE175 and IE110 provided direct evidence for partial redistribution of IE175 into the same punctate granules that contained IE110. Surprisingly, nuclear forms of IE110 were found to move a cytoplasmic form of IE175 into nuclear punctate structures, and a cytoplasmic form of IE110 was able to retain nuclear forms of IE175 in cytoplasmic punctate structures. Therefore, the punctate characteristic of IE110 appeared to both dominate the interactions and override the normal nuclear localization signals. The domains responsible for the interaction mapped to between codons 518 and 768 in 1E110 and to between codons 835 and 1029 in IE175. Importantly, a truncated nuclear form of the 1,298-amino-acid IE175 protein, which lacked the C-terminal domain beyond codon 834, was found to be excluded from the IE110 punctate granules. Cotransfection of nuclear or cytoplasmic IE110 with a truncated nuclear form of IE63 also led to partial redistribution of IE63 into either nuclear or cytoplasmic punctate granules containing IE110. Both the IE63-IE110 and IE175-IE110 colocalization interactions were demonstrated in Vero cells but not in 293 cells. Consequently, they differ from IE110 self-interactions, which correlate with in vitro dimerization and occur efficiently in both cell types. These interactions may help to explain the altered promoter target specificity and synergism observed when IE175 is cotransfected with IE110 in transactivation studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7983744      PMCID: PMC188596          DOI: 10.1128/JVI.69.1.476-491.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  Herpes simplex virus alpha protein ICP27 can inhibit or augment viral gene transactivation.

Authors:  L Su; D M Knipe
Journal:  Virology       Date:  1989-06       Impact factor: 3.616

2.  Three trans-acting regulatory proteins of herpes simplex virus modulate immediate-early gene expression in a pathway involving positive and negative feedback regulation.

Authors:  P O'Hare; G S Hayward
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

3.  Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1.

Authors:  D J McGeoch; A Dolan; S Donald; D H Brauer
Journal:  Nucleic Acids Res       Date:  1986-02-25       Impact factor: 16.971

4.  Promiscuous trans activation of gene expression by an Epstein-Barr virus-encoded early nuclear protein.

Authors:  P M Lieberman; P O'Hare; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

5.  A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein.

Authors:  J A Dyck; G G Maul; W H Miller; J D Chen; A Kakizuka; R M Evans
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

6.  A novel arrangement of zinc-binding residues and secondary structure in the C3HC4 motif of an alpha herpes virus protein family.

Authors:  R D Everett; P Barlow; A Milner; B Luisi; A Orr; G Hope; D Lyon
Journal:  J Mol Biol       Date:  1993-12-20       Impact factor: 5.469

7.  The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency.

Authors:  W Cai; T L Astor; L M Liptak; C Cho; D M Coen; P A Schaffer
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells.

Authors:  K Weis; S Rambaud; C Lavau; J Jansen; T Carvalho; M Carmo-Fonseca; A Lamond; A Dejean
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

9.  Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0).

Authors:  G G Maul; H H Guldner; J G Spivack
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

10.  Varicella-zoster virus open reading frame 4 encodes a transcriptional activator that is functionally distinct from that of herpes simplex virus homology ICP27.

Authors:  L P Perera; S Kaushal; P R Kinchington; J D Mosca; G S Hayward; S E Straus
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  28 in total

1.  Identification of a motif in the C terminus of herpes simplex virus regulatory protein ICP4 that contributes to activation of transcription.

Authors:  James W Bruce; Kent W Wilcox
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Components of the REST/CoREST/histone deacetylase repressor complex are disrupted, modified, and translocated in HSV-1-infected cells.

Authors:  Haidong Gu; Yu Liang; Gail Mandel; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

3.  Translocation and colocalization of ICP4 and ICP0 in cells infected with herpes simplex virus 1 mutants lacking glycoprotein E, glycoprotein I, or the virion host shutoff product of the UL41 gene.

Authors:  Maria Kalamvoki; Jianguo Qu; Bernard Roizman
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

4.  Promoter- and cell-specific transcriptional transactivation by the Kaposi's sarcoma-associated herpesvirus ORF57/Mta protein.

Authors:  Diana Palmeri; Sophia Spadavecchia; Kyla Driscoll Carroll; David M Lukac
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

5.  HCF-dependent nuclear import of VP16.

Authors:  S La Boissière; T Hughes; P O'Hare
Journal:  EMBO J       Date:  1999-01-15       Impact factor: 11.598

6.  Overexpression of the herpes simplex virus type 1 immediate-early regulatory protein, ICP27, is responsible for the aberrant localization of ICP0 and mutant forms of ICP4 in ICP4 mutant virus-infected cells.

Authors:  Z Zhu; N A DeLuca; P A Schaffer
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Mutational analysis of ICP0R, a transrepressor protein created by alternative splicing of the ICP0 gene of herpes simplex virus type 1.

Authors:  S J Spatz; E C Nordby; P C Weber
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  Herpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3' ends of labile mRNA.

Authors:  C R Brown; M S Nakamura; J D Mosca; G S Hayward; S E Straus; L P Perera
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.

Authors:  Y Xu; J H Ahn; M Cheng; C M apRhys; C J Chiou; J Zong; M J Matunis; G S Hayward
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies.

Authors:  L Szekely; K Pokrovskaja; W Q Jiang; H de The; N Ringertz; G Klein
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.